| |
| |
|
| Insider
Information: |
Lin Shao-Lee |
| Relationship: |
Chief Executive Office... |
| City: |
Dublin |
| State: |
L2 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
1,718,758 |
|
|
Indirect Shares
|
1,874,955 |
|
|
| Direct
Value |
$9,886,158 |
|
|
|
Indirect Value
|
$8,156,054 |
|
|
| Total
Shares |
3,593,713 |
|
|
| Total
Value |
$18,042,212 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -127.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Horizon Pharma, Inc. |
HZNP |
EVP, Head of R&D and CSO |
2020-01-05 |
106,255 |
2019-01-04 |
0 |
Premium* |
|
|
Surrozen Ord Shs |
SRZN |
Director |
2021-08-11 |
35,129 |
|
0 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
Chief Executive Office... |
2024-04-01 |
1,577,374 |
2024-04-01 |
1,874,955 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2024-04-01 |
4 |
S |
$6.63 |
$66,024 |
D/D |
(9,961) |
1,577,374 |
0 |
% |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2024-02-20 |
4 |
S |
$7.60 |
$119,403 |
D/D |
(15,701) |
1,587,335 |
0 |
% |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2024-01-02 |
4 |
S |
$7.41 |
$79,188 |
D/D |
(10,691) |
1,603,036 |
0 |
% |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-10-04 |
4 |
A |
$0.00 |
$0 |
I/I |
132,236 |
487,205 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-10-04 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,161,747) |
0 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
842,400 |
1,612,434 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-05-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,161,747 |
1,161,747 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-05-09 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,107,213) |
0 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
1,107,213 |
1,107,213 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-05-09 |
4 |
D |
$24.69 |
$8,324,950 |
D/D |
(337,179) |
770,034 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-05-09 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,742,719) |
0 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive Officer |
• • – |
2023-05-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,742,719 |
5,070 |
0 |
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive OfficerOfficer |
• • – |
2023-05-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,742,719 |
|
- |
|
| SLRN |
Acelyrin, Inc. |
Chief Executive OfficerOfficer |
• • – |
2023-05-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,107,213 |
|
- |
|
| SRZN |
Surrozen Ord Shs |
Director |
– • – |
2021-08-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,129 |
|
% |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2020-01-05 |
4 |
D |
$36.10 |
$1,375,410 |
D/D |
(38,100) |
106,255 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2020-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
35,652 |
144,355 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2020-01-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,344 |
108,703 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2020-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,892 |
66,472 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2020-01-04 |
4 |
D |
$36.10 |
$292,879 |
D/D |
(8,113) |
58,359 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2019-02-20 |
4 |
D |
$21.54 |
$340,224 |
D/D |
(15,795) |
47,531 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2019-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
35,652 |
63,326 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2019-01-05 |
4 |
D |
$20.39 |
$292,331 |
D/D |
(14,337) |
27,674 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2019-01-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,362 |
42,011 |
0 |
- |
|
| HZNP |
Horizon Pharma, Inc. |
EVP, Head of R&D and CSO |
• – – |
2019-01-04 |
4 |
D |
$20.39 |
$168,054 |
D/D |
(8,242) |
9,649 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
